Anti-human 4-1BB antibodies and uses thereof
Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFNγ, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.
1. An anti-4-1BB antibody or antigen-binding fragment thereof, comprising:
(a) a heavy chain CDR1 comprising a sequence of SEQ ID NO: 5, a heavy chain CDR2 comprising a sequence of SEQ ID NO: 6 and a heavy chain CDR3 comprising a sequence of SEQ ID NO: 7 or 8; and
(b) a light chain CDR1 comprising a sequence of SEQ ID NO: 1, a light chain CDR2 comprising a sequence of SEQ ID NO: 2 and a light chain CDR3 comprising a sequence of SEQ ID NO: 4.
2. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises:
(a) a heavy chain framework 1 (FR1) region comprising a sequence of SEQ ID NO: 16 or 17; and/or
(b) a heavy chain framework 3 (FR3) region comprising a sequence of any one of SEQ ID NOs: 18-20.
3. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises any one of the following:
(a) a heavy chain variable domain comprising a sequence at least 98% identical to a sequence selected from SEQ ID NOs: 11-14;
(b) a light chain variable domain comprising a sequence at least 98% identical to a sequence of SEQ ID NO: 10; or
(c) a heavy chain variable domain comprising a sequence at least 98% identical to a sequence selected from SEQ ID NOs: 11-14 and a light chain variable domain comprising a sequence at least 98% identical to a sequence of SEQ ID NO: 10.
4. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises any one of the following:
(a) a heavy chain variable domain comprising a sequence selected from SEQ ID NOs: 11-14;
(b) a light chain variable domain comprising a sequence of SEQ ID NO: 10; or
(c) a heavy chain variable domain comprising a sequence selected from SEQ ID NOs: 11-14 and a light chain variable domain comprising a sequence of SEQ ID NO: 10.
5. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment has a binding affinity (K D ) for a human 4-1BB molecule of 1×10 −7 to 1×10 −12 M.
6. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment binds to an epitope within the extracellular domain of human 4-1BB polypeptide.
7. The anti-4-1BB antibody or antigen-binding fragment of claim 6 , wherein the binding to an epitope within the extracellular domain of human 4-1BB is abrogated by one or more mutations at positions N30, D38, N39, and R41 of SEQ ID NO: 44.
8. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment fails to bind or weakly binds a canine 4-1BB polypeptide.
9. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment is or comprises a humanized antibody.
10. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody includes an immunoglobulin constant domain, wherein the constant domain is selected from an IgG1, an IgG2, an IgG4, an IgA, an IgE, an IgM, and an IgD.
11. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody is or comprises a human IgG1.
12. The anti-4-1BB antibody or antigen-binding fragment of claim 11 , wherein the IgG1 is or comprises a sequence that is at least 95% identical to SEQ ID NO: 22 or 23.
13. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment is a monoclonal antibody.
14. The anti-4-1BB antibody or antigen-binding fragment of claim 1 , wherein the antibody fragment is a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, or a scFv fragment.
15. A pharmaceutical composition comprising:
(a) the anti-4-1BB antibody or antigen-binding fragment of claim 1 ; and
(b) a pharmaceutically acceptable carrier.